EftekhariP, RoegelJ-C, Lezoualc’hF, et al.Induction of neonatal lupus in pups of mice immunized with synthetic peptides derived from amino acid sequences of the serotoninergic 5-HT4 receptor. Eur J Immunol, 2001; 31(2):573–579; doi: 10.1002/1521-4141(200102)31:2<573::AID-IMMU573>3.0.CO;2-9
2.
MarsM, NéantI, LeclercC, et al.Cav1.4 calcium channels control cytokine production by human peripheral TH17 cells and psoriatic skin-infiltrating T cells. J Allergy Clin Immunol, 2022; 149(4):1348–1357; doi: 10.1016/j.jaci.2021.09.030
3.
ChuangS-Y, LinC-H, SungCT, et al.Murine models of psoriasis and their usefulness for drug discovery. Expert Opin Drug Discov, 2018; 13(6):551–562; doi: 10.1080/17460441.2018.1463214
4.
ZhaoJ, HanM, ZhouL, et al.TAF and TDF attenuate liver fibrosis through NS5ATP9, TGFβ1/Smad3, and NF-κB/NLRP3 inflammasome signaling pathways. Hepatol Int, 2020; 14(1):145–160; doi: 10.1007/s12072-019-09997-6
5.
LiL, ZhaoJ, ZhouL, et al.Tenofovir alafenamide fumarate attenuates bleomycin-induced pulmonary fibrosis by upregulating the NS5ATP9 and TGF-β1/Smad3 signaling pathway. Respir Res, 2019; 20(1):163; doi: 10.1186/s12931-019-1102-2
6.
RohPR, KimSM, KangB-Y, et al.Tenofovir alafenamide alleviates nonalcoholic steatohepatitis in mice by blocking the phosphorylation of AKT in intrahepatic mononuclear phagocytes. Biomed Pharmacother, 2022; 156:113952; doi: 10.1016/j.biopha.2022.113952
7.
RenJ, DengG, LiR, et al.Possible pharmacological targets and mechanisms of sivelestat in protecting acute lung injury. Comput Biol Med, 2024; 170:108080; doi: 10.1016/j.compbiomed.2024.108080
8.
BaliKK, KunerR. Therapeutic potential for leukocyte elastase in chronic pain states harboring a neuropathic component. PAIN, 2017; 158(11):2243–2258; doi: 10.1097/j.pain.0000000000001032
9.
StruyfF, MertensMG, Navarro-LedesmaS. Causes of shoulder dysfunction in diabetic patients: A review of literature. Int J Environ Res Public Health, 2022; 19(10):6228; doi: 10.3390/ijerph19106228
10.
SemeranoL, DuvalletE, BelmellatN, et al.Targeting VEGF-A with a vaccine decreases inflammation and joint destruction in experimental arthritis. Angiogenesis, 2016; 19(1):39–52; doi: 10.1007/s10456-015-9487-0
RoseberryK, Le-NiculescuH, LeveyDF, et al.Towards precision medicine for anxiety disorders: Objective assessment, risk prediction, pharmacogenomics, and repurposed drugs. Mol Psychiatry, 2023; 28(7):2894–2912; doi: 10.1038/s41380-023-01998-0
13.
ClemowDB, WalkerDJ. The Potential for misuse and abuse of medications in ADHD: A review. Postgrad Med, 2014; 126(5):64–81; doi: 10.3810/pgm.2014.09.2801
EvansAH, LawrenceAD, LeesAJ. Changes in psychomotor effects of L-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson’s disease. J Neurol Neurosurg Psychiatry, 2009; 80(3):267–272; doi: 10.1136/jnnp.2006.108993
16.
DevosD, MoreauC, DelvalA, et al.Methylphenidate: A treatment for Parkinson’s disease? CNS Drugs, 2013; 27(1):1–14; doi: 10.1007/s40263-012-0017-y
17.
RyuminaII, GoryunovKV, SilachevDN, et al.Pathogenetic therapy of epidermolysis bullosa: Current state and prospects. Bull Exp Biol Med, 2021; 171(1):109–121; doi: 10.1007/s10517-021-05182-8
18.
CondorelliAG, LogliE, CianfaraniF, et al.MicroRNA‐145‐5p regulates fibrotic features of recessive dystrophic epidermolysis bullosa skin fibroblasts. Br J Dermatol, 2019; 181(5):1017–1027; doi: 10.1111/bjd.17840
19.
DongZ, HuoJ, LiangA, et al.Gamma-Secretase Inhibitor (DAPT), a potential therapeutic target drug, caused neurotoxicity in planarian regeneration by inhibiting Notch signaling pathway. Sci Total Environ, 2021; 781:146735; doi: 10.1016/j.scitotenv.2021.146735
20.
KeamSJ. Nirogacestat: First approval. Drugs, 2024; 84(3):355–361; doi: 10.1007/s40265-024-02002-x
21.
FriedL, KirsnerRS, BhandarkarS, et al.Efficacy of rapamycin in scleroderma: A case study. Lymphat Res Biol, 2008; 6(3-4):217–219; doi: 10.1089/lrb.2008.1006
22.
SuT-IK, KhannaD, FurstDE, et al.Rapamycin versus methotrexate in early diffuse systemic sclerosis: Results from a randomized, single‐blind pilot Study. Arthritis Rheum, 2009; 60(12):3821–3830; doi: 10.1002/art.24986
23.
TamakiZ, AsanoY, KuboM, et al.Effects of the immunosuppressant rapamycin on the expression of human α2(I) collagen and matrix metalloproteinase 1 genes in scleroderma dermal fibroblasts. J Dermatol Sci, 2014; 74(3):251–259; doi: 10.1016/j.jdermsci.2014.02.002
24.
SzymonowiczKA, ChenJ. Biological and clinical aspects of HPV-related cancers. Cancer Biol Med, 2020; 17(4):864–878; doi: 10.2089/2/j.issn.2095-3941.2020.0370
25.
BasukalaO, BanksL. The not-so-good, the bad and the ugly: HPV E5, E6 and E7 oncoproteins in the orchestration of carcinogenesis. Viruses, 2021; 13(10):1892; doi: 10.3390/v13101892
26.
MiyauchiS, SandersPD, GuramK, et al.HPV16 E5 mediates resistance to PD-L1 blockade and can be targeted with rimantadine in head and neck cancer. Cancer Res, 2020; 80(4):732–746; doi: 10.1158/0008-5472.CAN-19-1771
27.
PiconeP, Di CarloM, NuzzoD. Obesity and Alzheimer’s disease: Molecular bases. Eur J Neurosci, 2020; 52(8):3944–3950; doi: 10.1111/ejn.14758
28.
KaeidiA, AmirteimouryM, ZareM-S, et al.Effects of valsartan on morphine tolerance and dependence in rats. Res Pharm Sci, 2021; 16(3):286–293; doi: 10.4103/1735-5362.314827
29.
Mongi-BragatoB, AvalosMP, GuzmánAS, et al.Enkephalin as a pivotal player in neuroadaptations related to psychostimulant addiction. Front Psychiatry, 2018; 9:222; doi: 10.3389/fpsyt.2018.00222
30.
BasmadjianOM, OcchieppoVB, MontemerloAE, et al.Angiotensin II involvement in the development and persistence of amphetamine-induced sensitization: Striatal dopamine reuptake implications. Eur J Neurosci, 2024; doi: 10.1111/ejn.16312
31.
HeymansS, LakdawalaNK, TschöpeC, et al.Dilated cardiomyopathy: Causes, mechanisms, and current and future treatment approaches. Lancet, 2023; 402(10406):998–1011; doi: 10.1016/S0140-6736(23)01241-2
32.
Sfichi-DukeL, Garcia-CazarinML, SumandeaCA, et al.Cardiomyopathy-causing deletion K210 in cardiac troponin T alters phosphorylation propensity of sarcomeric proteins. J Mol Cell Cardiol, 2010; 48(5):934–942; doi: 10.1016/j.yjmcc.2010.01.005
33.
DuC-K, MorimotoS, NishiiK, et al.Knock-in mouse model of dilated cardiomyopathy caused by troponin mutation. Circ Res, 2007; 101(2):185–194; doi: 10.1161/CIRCRESAHA.106.146670
34.
ClemensJQ, EricksonDR, VarelaNP, et al.Diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol, 2022; 208(1):34–42; doi: 10.1097/JU.0000000000002756
35.
JiangY-H, KuoY-C, JhangJ-F, et al.Repeated intravesical injections of platelet-rich plasma improve symptoms and alter urinary functional proteins in patients with refractory interstitial cystitis. Sci Rep, 2020; 10(1):15218; doi: 10.1038/s41598-020-72292-0
36.
JhangJ-F, JiangY-H, LinT-Y, et al.The tumor necrosis factor-α level in platelet-rich plasma might be associated with treatment outcome in patients with interstitial cystitis/bladder pain syndrome or recurrent urinary tract infection. Int J Mol Sci, 2024; 25(1):163; doi: 10.3390/ijms25010163
37.
MassellaL, MekahliD, ParipovićD, et al.Prevalence of hypertension in children with early-stage ADPKD. Clin J Am Soc Nephrol, 2018; 13(6):874–883; doi: 10.2215/CJN.11401017
38.
ChebibFT, HoganMC, El-ZoghbyZM, et al.Autosomal dominant polycystic kidney patients may be predisposed to various cardiomyopathies. Kidney Int Rep, 2017; 2(5):913–923; doi: 10.1016/j.ekir.2017.05.014
39.
LorthioirA, JoannidèsR, Rémy-JouetI, et al.Polycystin deficiency induces dopamine-reversible alterations in flow-mediated dilatation and vascular nitric oxide release in humans. Kidney Int, 2015; 87(2):465–472; doi: 10.1038/ki.2014.241
40.
ThakurS, GuptaSK, AliV, et al.Aldose reductase: A cause and a potential target for the treatment of diabetic complications. Arch Pharm Res, 2021; 44(7):655–667; doi: 10.1007/s12272-021-01343-5
41.
CotterM, CameronN, RobertsonS, et al.Polyol pathway-related skeletal muscle contractile and morphological abnormalities in diabetic rats. Exp Physiol, 1993; 78(2):139–155; doi: 10.1113/expphysiol.1993.sp003675
42.
Briso-MontianoA, Del Caño-OchoaF, VilasA, et al.Insight on molecular pathogenesis and pharmacochaperoning potential in phosphomannomutase 2 deficiency, provided by novel human phosphomannomutase 2 structures. J Inherit Metab Dis, 2022; 45(2):318–333; doi: 10.1002/jimd.12461
43.
IyerS, SamFS, DiPrimioN, et al.Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG. Dis Model Mech, 2019; 12(11):dmm040584; doi: 10.1242/dmm.040584
44.
LigezkaAN, RadenkovicS, SaraswatM, et al.Sorbitol is a severity biomarker for PMM2-CDG with therapeutic implications. Ann Neurol, 2021; 90(6):887–900; doi: 10.1002/ana.26245
